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Anaplastic thyroid carcinoma (ATC) is a 
rare thyroid cancer characterized by  a 
rapid fatal course.  It is an 
undifferentiated form of cancer resistant 
to radiotherapy and chemotherapy. 
Surgery is rarely performed.
It is resistant to the radio-iodine therapy 
because it is lacking of the NIS 
symporter, marker of differentiated 
thyroid. 
Radio-iodine therapy id the therapy of 
election for the treatment of Thyroid 
cancers. 
Trans-activation: A New Epigenetic 
Phenomenon Underlying Transcriptional 
Memory (Arancio W, Onorati MC, Corona 
DF et Al; manuscript in preparation).
Using PEV assays, non-functional alleles 
can trans-activate the expression of wild 
type copy of the same gene. Data 
strongly suggest that cells can 'read' the 
presence of RNAs and can use them to 
maintain their transcriptional memory 
after cell division. If the phenomenon is 
conserved, it could be used as a 
therapeuthical strategy for ATC.
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The sodium/iodide symporter (NIS) 
mediates iodide uptake in the thyroid 
gland. NIS is detected in most thyroid 
cancer specimens, and it is sufficient to 
utilize radioactive iodide for the treatment 
of residual and metastatic disease.  
Approximately 10% of differentiated thyroid 
cancers and all ATC, do not express the 
NIS gene. These tumors are generally 
associated with a poor prognosis.
Several constructs have 
been made from NIS gene. 
ATC cell line SW1736 have 
been transiently transfected
5'UTR EXON I INTRON i EXON 2
The effects of transient transfection have 
been tested in RT-PCR using specific 
primers able to discriminate between 
constructs and genomics
The effects of stable transfection have been 
tested in RT-PCR. Unexpectedly, the effect 
was nullified by an unknown mechanism.
We tested if DNA methylase inhibitors can 
rescue the phenotype.
We identified a cocktail of DNA methyl 
transferase inhibitors (nucleotidic and not 
nucleotidic) that strongly induce the 
expression of NIS in the ATC cell line 
SW1736 (45X), independently from the 
transfection. 
The expression is even 3 times greater than 
the expression of NIS in control thyroids 
(data not shown). 
Moreover the cocktail results to be extremely 
toxic to the ATC cell line even at very low 
concentration (data not shown). 
DNMTi cocktail is highly citotoxic for 
the SW1736 ATC cell line and strongly 
induce NIS expression
ZEBularine 100 uM + RG108 50uM; 72 Hrs
ATC is up to date an untreatable form of 
cancer, resistant  to any therapy, with poor 
prognosis and rapid fatal course.
Our preliminary data suggest that a 
specific cocktail of DNA methyl transferase 
inhibitors can kill ATC cells per se. 
Moreover the treatment strongly induce the 
expression of NIS, sensitizing them to the 
treatment with radio-iodine.
These data suggest a possible 
pharmacological healing strategy for ATC.
To Do list...
CONCLUSIONS
● Testing Dose and Time dependence
● Testing other ATC cell lines
● Testing expression of NIS protein
● In vitro Functional assays
● In vivo assays
● Et cetera...
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